GreenX4Drug · Green Enantioselective Halogenation for Drug Discovery and Manufacture
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2019-04-01 → 2023-12-31
- EU contribution
- €607,200
- Participants
- 3
- Scheme
- MSCA-RISE
Lines connect the coordinator with its partners.
Results in brief
Green Enantioselective Halogenation for Drug Discovery and Manufacture
Issue Addressed: The European pharmaceutical industry confronts challenges such as patent expirations and stricter environmental regulations, prompting a shift towards sustainable practices. GreenX4Drug has tackled these issues by pioneering eco-friendly methodologies for pharmaceutical synthesis. Importance for Society: GreenX4Drug meets societal demands for accessible healthcare and environmental responsibility. By developing greener manufacturing processes, the project reduces the ecological impact of pharmaceutical production while addressing public health needs. Objectives: 1. Develop "Green" Organocatalysts: GreenX4Drug aims to create efficient organocatalysts, reducing reliance on expensive and harmful metal catalysts in pharmaceutical synthesis. 2. Establish Halogenation Platform: The project seeks to demonstrate the versatility of these catalysts in halogenation processes, providing a synthetic platform for pharmaceutical compound preparation. 3. Synthesise Drugs: Production of halogenated pharmaceuticals and intermediates. 4. Scale-up: Demonstrating industrial viability by scaling up synthesis using batch and continuous flow methodologies. Conclusions: GreenX4Drug has pioneered sustainable pharmaceutical manufacturing, addressing societal healthcare needs while promoting environmental stewardship. By leveraging academic and industry expertise, the project developed cost-effective and eco-friendly processes with the potential to transform the industry. While some deviations occurred, the project substantially achieved its scientific objectives, including the successful development of novel chiral scaffolds and methodologies for fast and selective synthesis of halogenated compounds. Ongoing evaluations aim to maintain enantiopurity, with adaptations for continuous flow methodology showing promise for scaled-up production.
Data: CORDIS, © European Union
Project objective
The aim of this project is to bring together subject matter experts from the academic and non-academic sectors to develop and exemplify the use of new catalysts and new green reactions to manufacture important halogenated compounds that could be used in drug discovery and drug production. In order to achieve this objective the proposal brings together 3 partners with complementary skills:University of Naples (UNINA): expertise in medicinal chemistry and drug discovery.KelAda Pharmachem: expertise in green chemistry, chemical batch process development and scale-up.UCO: expertise in process engineering of continuous flow processes.We have broken this proposal into the following separate technical Work Packages:WP1: Preparation of new catalysts for efficient desymmetrization [WP Leader: UNINA].WP2: Development of enantiospecific halogenation including Fluorination. [WP Leader: Kelada Pharmachem].WP3 Drug Candidate, library creation & in vitro testing. [WP Leader: Kelada Pharmachem]WP4 Development of flow variant and scale-up.[WP Leader: UCO}The above WP's will be undertaken via a series of interlinked secondment of researchers between the consortium partners and will be complemented by a series of training and other initiatives to facilitate interdisciplinary and inter-sectoral knowledge sharing and exchange.
Original text from CORDIS.
Participants
Links
- View on CORDIS
- DOI: 10.3030/823939
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e508f07bf0&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e508fc7101&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e508fdbbed&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e50933c8a1&appId=PPGMS
- https://greenx4drug.wordpress.com/
- https://www.ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c478b50e&appId=PPGMS
Data: CORDIS, © European Union
